NCT03995784View on ClinicalTrials.gov

Study of Next-Generation Recombinant Factor IX Variant in Adult Subjects With Hemophilia B

PHASE2CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

June 18, 2019

Primary Completion Date

February 28, 2020

Study Completion Date

April 30, 2020

Conditions
Hemophilia B
Interventions
BIOLOGICAL

Coagulation Factor IX variant

Single intravenous injection of CB2679d/Dalcinonacog alfa

BIOLOGICAL

Coagulation Factor IX variant

Daily subcutaneous injections of CB2679d/Dalcinonacog alfa for 28 days

Trial Locations (1)

Unknown

Haemophilia Comprehensive Care Centre, Johannesburg

Sponsors
All Listed Sponsors
lead

Catalyst Biosciences

INDUSTRY